Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

5225 - Survival analysis of sorafenib in hepatocellular carcinoma patients with microvascular invasion after hepatectomy

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Tumour Site

Hepatobiliary Cancers

Presenters

Zeyu Zhang

Citation

Annals of Oncology (2018) 29 (suppl_8): viii670-viii682. 10.1093/annonc/mdy304

Authors

Z. Zhang, Y. Huang, Y. Zhou, J. Yang, K. Hu, Z. Wang

Author affiliations

  • Department Of Hepatobiliary Surgery, Xiangya Hospital of Central South University, 410008 - Changsha/CN

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5225

Background

Hepatocellular carcinoma (HCC) is the most common primary liver cancer. The recurrence rate after hepatectomy remains high, which seriously affects the prognosis. Microvascular invasion (MVI) has been proved to be an independent risk factor for the recurrence of liver cancer. If patients with MVI can receive timely and effective treatment, it will help reduce the recurrence rate, and prolong the survival time. The aim of the study was to analyze the effect of sorafenib on the clinical outcomes in HCC patients with MVI after hepatectomy.

Methods

Patients with HCC who underwent hepatectomy and were pathologically diagnosed as MVI at the research center between January 2009 and December 2016 were retrospectively analyzed. Patients were divided into sorafenib group and control group according to whether or not sorafenib (Nexavar®) was taken after surgery. Sorafenib was administered orally, 0.4 g each time, twice daily. Follow-up was performed after hepatectomy. The recurrence-free survival (RFS) and overall survival (OS) were observed. Associated factors were analyzed using univariate and multivariate COX regression.

Results

This study included 16 patients in the sorafenib group and 33 patients in the control group. There was no significant difference in age, gender, hepatitis B surface antigen level, preoperative prethrombin time (PT), BCLC stage, preoperative a-fetoprotein level, maximum tumor diameter, and tumor number (all P < 0.05). The RFS and OS were both longer in the sorafenib group (both P < 0.05). The three-year RFS rates of the sorafenib group and the control group were 9 (56.3%) and 8 (24.2%), respectively, with significant difference (P = 0.027). The three-year OS rates of the sorafenib and control group were 13 (81.3%) and 13 (39.4%), respectively, with significant differences (P = 0.006). The results of multivariate COX regression indicated that preoperative PT and sorafenib treatment were the independent associated factors for RFS and OS.

Conclusions

The use of sorafenib after hepatectomy in HCC patients with MVI can prolong survival time.

Clinical trial identification

Legal entity responsible for the study

Zhiming Wang.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.